Top Stories
Rocket sold its paediatric voucher for $180 million, Enliven raised $400 million, and rare anaemia data for HUTCHMED's sovleplenib.
The US nod was supported by LITESPARK-022 study data showing a 28% disease-free survival benefit.
The companies suggested results from the Phase III LAGOON study may have been affected by an "unexpected overall survival outperformance" of the control arm.
Summit abandoned plans to raise $500 million, while Novo Nordisk said some pieces of patient data were accessed in a security incident.
A Phase III trial of the antibody oligonucleotide conjugate is already enrolling patients with facioscapulohumeral muscular dystrophy.
Conference News
EBERBACH, Germany and SIOUX CITY, Iowa, June 12, 2026 /PRNewswire/ -- GELITA, a global leader in collagen protein solutions, will showcase its latest excipient technology at BIO International 2026 in ...
- JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors -- Selective JAK V617F inhibitor, CGT1145,...
-- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an updated objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria –--...
Data from the RALLY-MF trial of DISC-0974 in patients with myelofibrosis (MF) and anemia demonstrate meaningful, durable overall anemia responses across all patient subgroups, regardless of baseline t...
TÜBINGEN, Germany, June 12, 2026 /PRNewswire/ -- Acousia Therapeutics GmbH, a clinical-stage biotechnology company pioneering treatments for acute and chronic inner ear hearing loss, today announced p...
